Indivior Announces Patrick Barry as Chief Commercial Officer
Rhea-AI Summary
Indivior PLC (Nasdaq/LSE: INDV) has appointed Patrick Barry as Chief Commercial Officer, effective June 2, 2025. Barry, a seasoned pharmaceutical executive with over 30 years of experience, will lead the company's commercial growth strategy and operations, focusing on advancing the treatment of opioid use disorder through SUBLOCADE®. Previously serving as executive vice president and chief commercial officer at Endo Pharmaceuticals, Barry managed commercial activities across three U.S. business segments with approximately $2 billion in revenue. His extensive career includes over two decades at Sanofi in various senior leadership positions. Barry holds an MBA from Cornell University and will join Indivior's executive committee.
Positive
- Appointment of highly experienced executive with 30+ years in pharmaceutical industry
- Strong track record in managing $2 billion revenue portfolio at Endo Pharmaceuticals
- Extensive experience in product launches and market development from Sanofi tenure
Negative
- None.
News Market Reaction – INDV
On the day this news was published, INDV gained 5.02%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Seasoned commercial executive with more than 30 years of pharmaceutical experience
"Patrick is an accomplished and respected commercial leader whose strong track record driving growth in branded medicines make him an excellent addition to the executive team," said Joe Ciaffoni, Chief Executive Officer. "Patrick's breadth and depth of commercial experience will be instrumental in delivering on the Company's potential."
Barry has more than 30 years of commercial leadership experience in the pharmaceutical industry. He brings a track record of building and transforming high-performing commercial organizations to deliver sustained revenue growth across multiple product portfolios.
Prior to joining Indivior, Barry served since 2020 as executive vice president and chief commercial officer for Endo Pharmaceuticals. In this role he led all commercial activities across three
"I am honored to join Indivior at such a pivotal time for the company," said Barry. "Indivior has built a strong foundation and is well-positioned to broaden its leadership position in opioid use disorder. I look forward to working with the team to grow SUBLOCADE and maximize the potential of the Indivior portfolio."
Prior to Endo, Barry spent over two decades at Sanofi with increasing levels of responsibility over a range of senior leadership positions, spanning specialty pharmaceuticals, injectables, medical aesthetics, and branded medicines, with demonstrated success in turnaround scenarios, product launches, and market development.
Barry holds an MBA from Cornell University and a bachelor's degree in public relations and marketing from McKendree University.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in
View original content to download multimedia:https://www.prnewswire.com/news-releases/indivior-announces-patrick-barry-as-chief-commercial-officer-302465432.html
SOURCE Indivior PLC
FAQ
Who is Patrick Barry, the new CCO of Indivior (INDV)?
When will Patrick Barry start as Indivior's Chief Commercial Officer?
What will be Patrick Barry's main responsibilities at Indivior (INDV)?
What is Patrick Barry's educational background?
